

FOR RELEASE ON April, 2025

MiCAN Technologies Inc.

Contact: Fushihara Kazuhisa, CFO

Tel: +81.75.381.3008

Email: info2@micantechnologies.com

MiCAN Establishes German Subsidiary for MylcMAT Deployment

MiCAN Technologies, Inc. (Headquarters: Kyoto, Japan; President: Kazuo Miyazaki) has established a subsidiary in Heidelberg, Germany. MiCAN Technologies EUROPA GmbH has started to offer a new thermogenic test product (MylcMAT®) for the European market, using immortalized monocyte cells (aMylc), which is a regenerative medicine technology.

Background of the Subsidiary Establishment in Germany

MiCAN Technologies has successfully developed immortalized monocyte cells (aMylc cells) specifically for pyrogen testing, utilizing its proprietary technology for creating immortalized hematopoietic cells. We have also developed a pyrogen test, MylcMAT®, based on these aMylc cells.

Currently, due to concerns for animal welfare and the quality control of new modality products such as regenerative medicine, monocyte activation tests (MAT) using human monocytic cell lines are attracting attention as an alternative to the conventional rabbit pyrogen test. This trend is particularly prominent in Europe, a leading region in animal welfare. To further expand our global presence, including in Europe, we have decided to establish a subsidiary in Germany.

Subsidiary Overview

- **Company Name:** MiCAN Technologies EUROPA GmbH
- **Address:** BioLabs Heidelberg, Nikola-Tesla-Straße 1, 69124 Heidelberg, Germany
- **Business Activities:**
 - Research and development, manufacturing, and sales of pharmaceuticals, research reagents, diagnostics, biotechnology, and healthcare-related products and technologies.
 - Contract research, development, and manufacturing.
 - Business management and consulting services for companies.
 - All business activities and investments related to the above.

- **Capital:** EUR 25,000
- **Establishment Date:** February 25, 2025



(Photo: Left – BioLabs exterior, Right – BioLabs lobby)

About BioLabs

A membership-based innovation platform and network of shared laboratory, BioLabs offers beautifully designed coworking environments that pair fully equipped and supported lab, office, and event spaces with relevant programming and unparalleled access to capital and industry partners.

These fertile, supportive ecosystems allow young companies to shift their focus from startup operations to experimentation and innovation so they can reach their scientific potential quickly and achieve business success.

Companies can start with a single lab bench and scale up as they grow.

The expanding BioLabs network currently operates labs in the US: California; Connecticut; Massachusetts; New Jersey; North Carolina; New York City; Pennsylvania; Texas; Vermont; in Europe, Paris and Saclay, France, Heidelberg and Berlin, Germany, and in Kawasaki, Japan.

Learn more at <https://www.biolabs.io/> and BioLabs Heidelberg.

Comment from Dr. Ann-Kristin Mueller, Site Director of BioLabs

We are delighted to have MiCAN Technologies at our site in Heidelberg, providing them with a unique launch pad into the European market at Germany's premier life-sciences hub in Heidelberg.

We are glad to see you grow and use the facilities and, most importantly, our international, pan-European network to explore new opportunities and markets.

About aMylc Cells

In 2019, MiCAN Technologies successfully developed immortalized myeloid cells (iMylc cells) derived from human iPS cells using regenerative medicine technology. (Myeloid

cells include monocytes, macrophages, and dendritic cells, which are types of white blood cells.)

Thanks to our immortalization technology, we can stably and continuously supply myeloid cells, which were previously difficult to obtain in large quantities. Utilizing this technology, we have successfully developed aMylc cells, which closely resemble human monocytes. In comparison of TLR (Toll-like receptor) responsiveness with peripheral blood mononuclear cells (PBMCs), aMylc cells demonstrated similar cytokine production capabilities.

About MylcMAT®

We have begun providing MylcMAT® for research use as a new MAT testing product utilizing aMylc cells. MAT tests have been included in pharmacopeias worldwide as an alternative to rabbit pyrogen tests. This method has already been adopted in Europe and India, and there is movement towards its inclusion in the Japanese Pharmacopeia in upcoming revisions.

About MiCAN Technologies Inc.

Since our establishment in 2016, we have supported the development of therapeutics and vaccines by providing research-use hematopoietic cells (Mpv, Mylc) through our proprietary immortalized hematopoietic cell technology. By supplying MylcMAT® products and developing the Mylc-SRIP business, we are committed to contributing to a society where people can live without fear of infectious diseases.

Address: Kyoto University Katsura Venture Plaza, 1-36 Goryo Oohara, Nishikyo-ku, Kyoto, Japan 615-8245

Website: www.micantechnologies.com